Anti CD47 drugs are a class of therapeutic antibodies that block the CD47 protein and aim to treat various types of cancers. CD47 acts as a “don’t eat me” signal to macrophages and prevents them from engulfing and destroying cancer cells. By blocking this protein, anti CD47 drugs help activate the body’s immune system to attack and eliminate cancer cells. They are being evaluated in clinical trials for hematologic as well as solid tumors either as monotherapy or in combination with other agents.
The Anti CD47 Drugs Market is projected to grow significantly in the coming years owing to rising cancer incidence worldwide and ongoing advancements in cancer immunotherapy.
The market is estimated to be valued at US$ 0.14 Bn in 2024 and is expected to exhibit a CAGR of 42% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the anti CD47 drugs are Bristol Myers Squibb, ALX Oncology, Trillium Therapeutics, Innovent Biologics, Forty Seven.
The rising prevalence of cancer globally has increased the demand for improved and targeted treatment options. Many pharmaceutical companies are actively conducting research to develop novel anti-cancer drugs with better efficacy and safety profiles. Anti CD47 drugs are viewed as a promising class of therapies that can help patients combat both hematologic as well as solid tumors.
Several pharmaceutical giants are also collaborating with biotech companies to expedite clinical development of anti CD47 drug candidates and expand their portfolios in the lucrative oncology segment. For instance, Bristol Myers Squibb has partnered with Trillium Therapeutics and Forty Seven to co-develop anti CD47 monoclonal antibodies. Such partnerships enable wider global development and commercialization of these drugs.
Market Key Trends
One of the key trends gaining traction in the Anti CD47 Drugs Market is their evaluation in combination with other immunotherapies or chemotherapy drugs. For example, ALX Oncology is studying ALX148 along with standard agents like trastuzumab and paclitaxel in HER2-positive breast cancer. Such combination regimens hold promise to yield improved and long-lasting responses by simultaneously targeting multiple pathways that limit anti-tumor immunity. As clinical evidence in support of combination strategies emerges, their demand is likely to grow significantly over the coming years.
Porter’s Analysis
Threat of new entrants: High capital requirement and long development period limit the number of new entrants in the Anti CD47 Drugs Market.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over smaller firms developing anti CD47 drugs.
Bargaining power of suppliers: Suppliers of raw materials have limited bargaining power due manufacturing process of anti CD47 drugs require specific raw materials with stringent quality controls.
Threat of new substitutes: No direct substitutes exist for anti CD47 drugs used in cancer treatment hence substitution threat is low.
Competitive rivalry: Large number of clinical trials and drug candidates indicate intense competition among existing players in the Anti CD47 Drugs Market.
The Anti CD47 Drugs Market in North America currently holds the largest share in terms of value owing to high healthcare spending and presence of global pharmaceutical companies.
The Anti CD47 Drugs Market in Asia Pacific is poised to grow at the fastest CAGR during the forecast period driven by rising healthcare awareness, increasing disposable income and growing focus of global players on emerging Asian countries.
What Are The Key Data Covered In This Anti CD47 Drugs Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Anti CD47 Drugs ‘s growth between 2024 and 2031.
:- Accurate calculation of the size of the Anti CD47 Drugs and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Anti CD47 Drugs Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Anti CD47 Drugs vendors
FAQ’s
Q.1 What are the main factors influencing the Anti CD47 Drugs ?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Anti CD47 Drugs companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Anti CD47 Drugs ’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it